Impiricus

New whitepaper..... When reviewing your marketing tactics, does the activity seem more multichannel than omnichannel? According to many HCPs, that is the case with many pharma brands. Why? Perhaps it is because many brand initiatives are focused on a select number of publications, websites, and closed "doctor-only" social media apps. HCPs operate outside these ecosystems. When they need your valuable resources, you want to be there for them. When HCPs need fingertip access to your message and support, we help you be present where and when they need you most. #omnichannel #pharmamarketing #hcpengagement #impiricus

Working with pharma it was amazing to see how little practicing physician voice was involved. We’re changing that. Watch the videos to see how pharma can truly serve physicians and patients.

Introducing the HCP Webinar Series. Hear physicians give their authentic views on the Pharma industry. Learn what doctors think about the future of Pharma-HCP engagement including rep interactivity, MSLs, patient support, and much more. Link to the series in the comments below. #hcp #pharma

When I posted recently about the Veeva vs Salesforce debate now that the two pharma CRM companies are breaking up, I got over 150 responses. Many hit on a common theme: Why just the two power-players when there are billions of dollars on the line? The answer reveals a lot about the pharma industry. Sadly, we are known more for being safe than for speedy innovation and risk taking. First, a reminder of the big decision facing pharma companies: Veeva is a cloud CRM service built on top of Salesforce that caters to life sciences companies, and the two have been partners since 2007 and dominate the market. But they are set to split in September 2025 and have already started competing, and pharma and other life science brands will have to choose. Veeva has 47 of the top 50 pharma brands worldwide as customers and topped $2 billion in annual revenue as a niche life science business, while Salesforce is far bigger and controls the overall CRM market with a 22% market share. In a normal market, the idea of a two-horse race wouldn’t make sense; you’d have Coke and Pepsi but you’d also have Dr. Pepper, Sprite, ginger ale, root beer, etc. That philosophy doesn’t really apply in pharma in most cases. It’s easy to see why: We are in a tightly-regulated industry with a lot more than money on the line. Many of our decisions affect the health of human lives - though certainly picking a cloud CRM offering has lower stakes than deciding which X-ray machine to pick. There will always be competition in business, and we will see more firms pop up to try and offer a “third way” in this split. I don’t want to count them out or diminish what they are doing. But they face long odds. One analysis found 128 competitors to Veeva who had a combined $737 million in funding raised - a drop in the bucket compared to Veeva’s $30 billion market cap. And Salesforce’s value is 8x Veeva’s. Some have or will be bought out by larger companies like Oracle, which will help them get on a closer playing field. I’d expect as the deadline to pick a new CRM draws near over the next 15 months or so that companies will sit back and watch which option the big firms choose, and then fall in line behind them. The old cliche “Nobody gets fired for buying IBM” is true in business as a whole, and doubly true in pharma.

The expected evolution of pharma interactions: Live from physicians. Join us and two physicians as they explore the expected evolution of pharma interactions. Impiricus https://brnw.ch/21wKNcj #sponsoredpodcast #pharma #physicians

📢 Announcing a new, free to enter, award category at the Fierce Pharma Marketing Awards, sponsored by Impiricus! HCP engagement is constantly evolving but the goal of delivering high-value content to physicians remains the same. The Impiricus HCP Impact Award highlights creative marketing initiatives that result in meaningful HCP impact, judged by the physicians themselves.   Use code IMPIRICUSHCP to enter: https://loom.ly/I9SqXro   #sponsored #FiercePharma #FierceBiotech #FierceLifeSciences #Marketing #FiercePharmaMarketingAwards #WeAreFierce

In their latest podcast MM+M is joined by Osama Hashmi MD MPH and Dr. Greene to discuss an important topic: the expected evolution of pharma interactions. HCP engagement is constantly evolving and brands are continually adapting. One thing stays the same — trying to connect healthcare professionals to the resources that give their patients the best access to care. Hear the expected evolution of pharma interactions from the valuable voice of the physician as they discuss the most pressing questions on pharma interaction. Listen here: https://lnkd.in/enHhW7Cu

Impiricus has been selected by CMI Media Group to enter into a strategic partnership to accelerate adoption of our capabilities in Pharma. During my discussions with the CMI leadership team, it became clear that partnering with CMI would be a game-changer for the industry. CMI brings 30+ years of experience focused on elevating health through the power of connected conversations. Our platform brings unprecedented access to HCPs with a mobile network of 800K+ opted in HCPs. This partnership will increase the Impiricus footprint and ensure more healthcare professionals are getting resources that give their patients the best access to care.

The Impiricus team is expanding and we’re looking for talented individuals to join our dynamic team. At Impiricus, we are dedicated to transforming how physicians and pharma companies interact through new technologies and data-driven solutions. We foster a collaborative and inclusive work environment where your ideas can thrive - your professional growth is our priority. Visit our Careers Page to explore our open positions and submit your application: https://lnkd.in/edQFEEve Join us as we revolutionize healthcare. #Hiring #Careers #JoinUs #HealthcareInnovation #TechJobs #Impiricus

The gold rush to capture a piece of the $100 billion market for the next big wonder drug is on, and the competition is going to get fierce. Hims & Hers, a telehealth company perhaps best known for offering a generic version of Viagra, is putting out a new Ozempic copycat drug that would be significantly cheaper than the name-brand versions, which are incredibly expensive without insurance and still difficult to find. Right now, Novo Nordisk and Eli Lilly dominate the GLP-1 weight loss/diabetes drug market through brands like Ozempic, Wegovy, Mounjaro and Zepbound. Almost all of the forecasted pharma growth worldwide is expected to come from this one drug class. There’s no way two companies are going to have a monopoly on these drugs, and we’ve been waiting to see what competitors will do. Hims & Hers is attempting the first big challenge to Novo and Lilly’s dominance. How they fare will not only forecast the future of the pharma industry but could impact how Americans get access to a drug that has the potential to drastically alleviate the obesity epidemic. Hims & Hers is offering its weight-loss shots for $199 a month - an 85% discount compared to Wegovy, which costs $1,350 without insurance. That’s a huge deal because A) the drugs sometimes aren’t covered, and B) you need to take it indefinitely for it to keep working, so the lifetime cost could be astronomical: 10 years of Wegovy would cost over $160,000 without insurance help. Given that Hims & Hers’ stock jumped as much as 38% the day of the GLP-1 announcement, it won’t be long until other companies follow suit. Typically drug companies are protected by competitors though patents that prevent generic versions from entering the market for a decade or more. In this case, U.S. regulations allow firms to make copycat drugs using “compounding” medications when drugs are in shortages. The FDA doesn’t approve compounded medications the way it does with name-brand prescriptions, so safety issues remain a concern. The agency has already advised patients not to take compounded versions of GLP-1 if patented FDA-approved versions are available. Still, the demand for the weight-loss pens are so high that people might be more willing to overlook those concerns if compounded versions are the only ones they can get their hands on. Even if supply issues improve for the name-brand pens, the massive cost difference might be enough for people to order the compounded versions.